tert-butyl N-[3-(isoquinolin-6-ylamino)-3-oxopropyl]-N-(4-phenacyloxyphenyl)carbamate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tert-butyl N-[3-(isoquinolin-6-ylamino)-3-oxopropyl]-N-(4-phenacyloxyphenyl)carbamate
• 化学式: C₃₁H₃₁N₃O₅
• 分子量: 525.6
• InChiKey: YXRNJMLUYBGKRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  39
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  97.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Dual mechanism inhibitors for the treatment of disease
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US10316029B2

  公开（公告）日：2019-06-11

  Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

  提供了同时抑制rho激酶和单胺转运体（MAT）的化合物，用于改善疾病状态或病情。此外还提供了包含这些化合物的组合物。进一步提供了使用该发明的化合物治疗疾病或病情的方法。其中一种疾病可能是青光眼，除了其他有益的效果外，还可以显著降低眼内压（IOP）。
• DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE
  申请人：AERIE PHARMACEUTICALS, INC.

  公开号：US20140187617A1

  公开（公告）日：2014-07-03

  Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

  提供了抑制Rho激酶和单胺转运体（MAT）的化合物，可用于改善疾病状态或情况。还提供了包含这些化合物的组合物。还提供了治疗疾病或情况的方法，该方法包括根据本发明给患者施用化合物。其中一种疾病可能是青光眼，除了其他有益的作用外，还可以显著降低眼内压（IOP）。
• US9951059B2
  申请人：——

  公开号：US9951059B2

  公开（公告）日：2018-04-24